Immunohistochemical profiles of brain metastases from breast cancer
- 162 Downloads
The aim of present study is to explore the immunohistochemical profiles of brain metastases from breast cancer. We retrospectively performed immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor type 2 (HER2/neu), and cytokeratin (CK) 5/6 in 29 patients with resected tumor specimens of brain metastases. Immunohistochemical staining for ER, PgR and HER2/neu was performed in 24 patients with primary tumors. The positive frequency of immunohistochemical profiles of ER, PgR, HER2/neu, and CK5/6, in the brain metastases were 13.8%, 6.9%, 37.9%, and 24.1%, respectively. The immunohistochemical profiles including ER, PgR, and HER2/neu of the primary tumor and the brain metastasis differed in seven patients (29.2%, N = 7/24). Interestingly, the biological characteristics of brain metastasis sometimes changed which were represented by immunohistochemical staining. Therefore, the changes in the biological features of breast cancer should be taken into account when developing treatment strategies, including new molecular-targeted drugs, for brain metastases.
KeywordsImmunohistochemical staining Discordance Hormone receptor HER2/neu Breast cancer Brain metastasis
This study was supported by grants from the Ministry of Health, Labour, and Welfare. The authors thank Kunihiko Seki, M.D. (Clinical Laboratory Division, National Cancer Center Hospital), Eriko Nakano, M.D., Mayu Yunokawa, M.D., Tsutomu Kouno, M.D., Masashi Ando, M.D., Noriyuki Katsumata, M.D., and Kenji Tamura, M.D., PhD. (Breast and Medical Oncology Division, National Cancer Center Hospital) for their assistance.
- 12.Perren A, Weng L-P, Boag AH et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinoma of the breast. Am J Pathol 155:1254–1260Google Scholar
- 21.Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER2/neu overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93:552–556. doi: 10.1038/sj.bjc.6602738 PubMedCrossRefGoogle Scholar
- 23.Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolce S et al (2001) Evaluation of HER2, p53, bcl-2, topoisomerase II-alfa, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 12:615–620. doi: 10.1023/A:1011182524684 PubMedCrossRefGoogle Scholar